INTRODUCTION

Angiogenic cellular processes by endothelial cells
Angiogenesis, or new blood vessel formation from pre-existing blood vessels, is a prerequisite for many normophysiological and pathophysiological conditions, such as cycles in female reproductive organs, embryonic development, regenerative medicine, collateral formation after occlusion of arteries, age-related macular degeneration, proliferative retinopathies, and malignant tumor growth/progression (1, 2) . Although angiogenesis is favorable in implantation of engineered tissues for regenerative medicine and in collateral formation as support for obstructive arteries, inhibition of angiogenesis leads to disease control for some types of eye diseases and advanced malignant tumors.
Classically, angiogenesis has been described as resulting from a series of cellular processes involving vascular endothelial cells, including the production of proteases to digest the basement membrane of blood vessels, thus allowing endothelial cells to migrate into surrounding tissue, survive, proliferate, and form a lumen (3) . Cultured endothelial cells can be used to examine this process separately, and in this context, fibroblast growth factors (FGFs), vascular endothelial growth factors (VEGFs), hepatocyte growth factor (HGF), and angiopoietins (Ang) have been found to stimulate almost all angiogenic cellular processes (4-7). In addition, the biochemical relevance of intracellular signaling molecules in each process has also been identified, such as phosphoinositide 3-kinase (PI3-kinase) and its downstream kinase, c-Akt, extracellular signal-regulated kinases/mitogen-activated protein kinase (ERK/MAPK), the c-Src family kinases, and c-Fes (8-11).
VEGF-A as a central player in angiogenesis
The VEGF family consists of five members, VEGF-A, -B, -C, -D, and placental growth factor (PlGF), and their signals are transduced into cells via VEGF receptor (VEGFR)-1, -2, and -3 (12, 13). The prototype VEGF, VEGF-A, binds to both VEGFR-1 and -2, whereas VEGF-B and PlGF exclusively bind to VEGFR-1. VEGFR-3 has been identified as a lymphatic endothelial cell receptor for VEGF-C and -D, which also bind to VEGFR-2. In general, the functional receptor for VEGF-A is VEGFR-2, while VEGFR-1 is thought to be a decoy receptor to regulate the concentration of VEGFR-2-associated VEGF-A (14) . signaling induces expression of VEGFR-1, but it inhibits VEGFR-2 expression (17, 18) . Another Notch1 ligand, Jagged1 (Jag1), has the opposite effect on
Notch1-inhibited tip cell formation (19) . Jag1 antagonizes Dll4-mediated Notch1 signals, which are regulated through modification of Notch1 by glycosyltransferases from the Fringe family. Jag1 is expressed in stalk cells, promoting their activation and maintaining the VEGF response.
Notch plays a role in VEGFR-3 regulation, as well. In the microvessels of early postnatal retina and growing tumors, VEGFR-3 becomes unregulated with inhibition of Notch signaling (20, 21) . Blockade of VEGFR-3 inhibits branching angiogenic sprouts (21) , suggesting that VEGFR-3 is also required for pathophysiological angiogenesis. Expression of VEGFR-3 decreases when Jag1 is deleted in tip cells (19) .
Ephrin-B2, a ligand of EphB4 receptor tyrosine kinase, also plays a role in this pathway and has been shown to regulate the internalization of VEGFR-2 and -3 (22, 23 The roles of VEGF-A/VEGFR-2 signaling in tumor progression have been studied extensively, and it is now widely recognized that VEGF-A is a key player in tumor angiogenesis. Initially, it was thought that anti-angiogenic therapies does not develop resistance because the targeted endothelium is genetically stable (26) . Therefore, many VEGF-targeting therapies, such as blocking antibodies against VEGF-A (e.g., bevacizumab) and small molecular weight synthetic protein kinase inhibitors for VEGF receptors (e.g., sunitinib and sorafenib), have been used in many types of cancers (27) . In general, however, the period of effectiveness is limited, and resistance to these therapies through multiple mechanisms has been reported (28, 29) . 
ROLES OF c-FES IN ANGIOGENIC PROCESSES INDUCED BY A VARIETY OF PROANGIOGENIC FACTORS
FGF
The FGF family is composed of 22 structurally related members (40) . 
Stromal cell-derived factor-1alpha
SDF-1alpha (also known as CXCL12) is one of the CXC chemokines, which share a consensus Glu-Leu-Arg motif preceding the first cysteine residue.
Its cognate receptor is CXCR4 (also known as CD184), which is a seven-transmembrane domain heterotrimeric G-protein-coupled receptor that is 
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